Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.
Open Access
- 2 September 2010
- journal article
- Published by Public Library of Science (PLoS) in PLoS Currents
- Vol. 2, RRN1172
- https://doi.org/10.1371/currents.rrn1172
Abstract
The family of histone deacetylases (HDACs) has recently emerged as important drug targets for treatment of slow progressive neurodegenerative disorders, including Huntington’s disease (HD). Broad pharmaceutical inhibition of HDACs has shown neuroprotective effects in various HD models. Here we examined the susceptibility of HDAC targets for drug treatment in affected brain areas during HD progression. We observed increased HDAC1 and decreased HDAC4, 5 and 6 levels, correlating with disease progression, in cortices and striata of HD R6/2 mice. However, there were no significant changes in HDAC protein levels, assessed in an age-dependent manner, in HD knock-in CAG140 mice and we did not observe significant changes in HDAC1 levels in human HD brains. We further assessed acetylation levels of α-tubulin, as a biomarker of HDAC6 activity, and found it unchanged in cortices from R6/2, knock-in, and human subjects at all disease stages. Inhibition of deacetylase activities was identical in cortical extracts from R6/2 and wild-type mice treated with a class II-selective HDAC inhibitor. Lastly, treatment with class I- and II-selective HDAC inhibitors showed similar responses in HD and wild-type rat striatal cells. In conclusion, our results show that class I and class II HDAC targets are present and accessible for chronic drug treatment during HD progression and provide impetus for therapeutic development of brain-permeable class- or isoform-selective inhibitors.Keywords
This publication has 32 references indexed in Scilit:
- Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin AcetylationJournal of Neuroscience, 2007
- Histone deacetylase inhibitors as therapeutics for polyglutamine disordersNature Reviews Neuroscience, 2006
- Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophyHuman Molecular Genetics, 2004
- Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease MiceJournal of Neuroscience, 2003
- Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeatsJournal of Comparative Neurology, 2003
- Transcriptional dysregulation in Huntington’s diseaseTrends in Neurosciences, 2000
- The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcriptionProceedings of the National Academy of Sciences of the United States of America, 2000
- Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3Journal of Neuroscience, 2000
- Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic MiceCell, 1996
- Evidence for Degenerative and Regenerative Changes in Neostriatal Spiny Neurons in Huntington's DiseaseScience, 1985